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Primary familial brain calcification (PFBC) is a rare neurodegenerative disorder characterized by a combination of neurological, psychi-
atric, and cognitive decline associated with calcium deposition on brain imaging. To date, mutations in five genes have been linked to
PFBC. However, more than 50% of individuals affected by PFBC have nomolecular diagnosis. We report four unrelated families present-
ing with initial learning difficulties and seizures and later psychiatric symptoms, cerebellar ataxia, extrapyramidal signs, and extensive
calcifications on brain imaging. Through a combination of homozygosity mapping and exome sequencing, we mapped this phenotype
to chromosome 21q21.3 and identified bi-allelic variants in JAM2. JAM2 encodes for the junctional-adhesion-molecule-2, a key tight-
junction protein in blood-brain-barrier permeability. We show that JAM2 variants lead to reduction of JAM2 mRNA expression and
absence of JAM2 protein in patient’s fibroblasts, consistent with a loss-of-function mechanism. We show that the human phenotype
is replicated in the jam2 complete knockout mouse (jam2 KO). Furthermore, neuropathology of jam2 KO mouse showed prominent
vacuolation in the cerebral cortex, thalamus, and cerebellum and particularly widespread vacuolation in the midbrain with reactive as-
trogliosis and neuronal density reduction. The regions of the human brain affected on neuroimaging are similar to the affected brain
areas in the myorg PFBC null mouse. Along with JAM3 and OCLN, JAM2 is the third tight-junction gene in which bi-allelic variants
are associated with brain calcification, suggesting that defective cell-to-cell adhesion and dysfunction of the movement of solutes
through the paracellular spaces in the neurovascular unit is a key mechanism in CNS calcification.Primary familial brain calcification (PFBC [MIM: 213600]),
often referred as Fahr disease, constitutes a heterogeneous
neurodegenerative disorder that presents with mineral
calcium deposits in the brain. The clinical manifestations
can include, but are not restricted to, movement disorders
such as parkinsonism and ataxia, seizures, migraine, and
neuropsychiatric symptoms. Both autosomal-dominant
and -recessive inheritance patterns have been reported.1
The clinical picture and severity are often variable be-
tween and within families, with some family members be-
ing clinically asymptomatic. The advent of widespread
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significantly increased the number of PFBC-affected fam-
ilies identified.2
There are two main pathogenic mechanisms described
so far in PFBC. On the one hand, the calcium and phos-
phate homeostasis dysfunction via dominant mutations
in SLC20A2 (MIM: 158378) and XPR1 (MIM: 605237).1
The inhibition of phosphate uptake by mutations in
SLC20A2 encoding for sodium-dependent phosphate
transporter 2 (PiT-2) leads to deposition of calcium in the
vascular extracellular matrix, and inhibition of phosphate
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Figure 1. Clinical and Neuroimaging Features of JAM2-Related Disease
(A) Pedigrees of the four families with bi-allelic JAM2 mutations.
(B) Brain images of JAM2-related disease. B1 to B3 are CT scans acquired from case subject F1-II:2 from family 1 and B4 to B6 are CT ac-
quired from case subject F2-III:3 from family 2. In both individuals there is extensive, symmetrical, bilateral calcification involving the
(legend continued on next page)
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increase intracellular phosphate concentration and pro-
voke calcium phosphate precipitation.3
On the other hand, the second mechanism causes PFBC
through disruption of the neurovascular unit (NVU).
Endothelial integrity and function affecting the blood-
brain barrier (BBB) is altered via dominant mutations in
PDGFB (MIM: 190040) and PDGFRB (MIM: 173410) encod-
ing for the platelet-derived growth factor B and its receptor,
that lead to the impairment of pericytes recruitment and
BBB integrity, causing vascular and perivascular calcium
accumulation.2 The recessive brain calcification pheno-
type due to MYORG4 (MIM: 618255) mutations, has been
shown to present specific myorg mRNA expression in
mouse astrocytes and disturb the normal function of the
NVU. Mutations in JAM35 (MIM: 613730) and OCLN6
(MIM: 602876) encoding for tight junction proteins lead
to excess solutes crossing the BBB causing CNS calcifica-
tion and hemorrhage.
Interestingly, a study on the Slc20a2 null mouse sug-
gested that the calcified nodules present in the brain initi-
ated in pericytes and astrocytes and found endogenous IgG
around nodules proposing that there was increased BBB
permeability7 and identifying a possible link between
different PFBC causative genes.
Pathologically, human brains exhibit calcium salt de-
posits predominantly distributed around small blood ves-
sels,2 and a reported subject with a SLC20A2mutation pre-
sented calcification in the tunica media of small arteries,
arterioles, and capillaries, but not in veins distributed in
the basal ganglia, thalamus, cerebellar white matter, and
deeper layers of the cerebral cortex.8
Despite important progress in discovering the genetic ar-
chitecture of PFBC, more than half of the case subjects
remain genetically unsolved.2
In this study we report four unrelated families with
seven individuals affected by autosomal-recessive primary
familial brain calcification. In the families described here,
we used a combination of homozygosity mapping, exome
sequencing (ES), functional studies, and mouse model to
identify and characterize the causal variants in JAM2
(MIM: 606870) encoding for the junctional-adhesion-
molecule-2, a tight-junction protein as a cause of PFBC.
Two unrelated consanguineous families from traveller
communities in England (family 1) and Northern Ireland
(family 2), one non-consanguineous family from the
United States (family 3) identified using GeneMatcher,
and one Turkish consanguineous family (family 4) were
included in this study (Figure 1A). Clinical features of
affected individuals are presented in Table 1. The proband
in family 1 (F1-II:2) had a normal birth and early mile-
stones. He presented with childhood-onset cerebellar
ataxia and learning difficulties. His symptoms progressedbasal ganglia, deep cortical gray matter and cerebellum. B7, 8, and 9
basal ganglia and cortical gyri but not in the cerebellum. B10, 11, a
showing basal ganglia and frontal calcification (B10 is T1 MRI, B11 is
sitive to calcium shown as hypointense regions). Asterisk (*) areas of
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and worsening cognitive impairment. He was examined
by a neurologist at the age of 23 years old. At that stage,
he already had difficulties following commands and had
alternate exotropia with left eye preference for fixation,
slow and jerky pursuit, and ophthalmoplegia. He had
reduced ability to control tongue movements and was un-
able to protrude his tongue. He was dysarthric with
dysphagia and a percutaneous endoscopic gastrostomy
(PEG) insertion at the age of 22 years. He had increased
tone in the upper and lower limbs with ankle contractures,
brisk reflexes throughout, and upgoing plantars. There was
upper and lower limb ataxia, bradykinesia, and generalized
dystonia, worse in the upper limbs (Video S1). Occasional
seizures were seen later in the disease course. The interictal
electroencephalography (EEG) showed moderate general-
ized slowing of cortical rhythms.
There were four affected individuals in the second fam-
ily. Two siblings (F2-III:2 and F2-III:3) presented with
borderline low IQ in childhood but had no definite phys-
ical limitations in early life. In their twenties they had so-
cial withdrawal and severe depression requiring treatment.
The disease progressed and examination at 41 and 39 years
revealed severe speech hypophonia, dysphagia, hypomi-
mia, reduced vertical up gaze, orofacial dyskinesias, slow
and reduced tongue movements with bradykinesia, and
dystonic limb posturing in both affected individuals.
Tone was increased in an extrapyramidal pattern with
lower limb hyperreflexia and extensor plantar responses,
grasp reflexes, positive glabellar tap, and brisk jaw jerk.
They both hadmemory decline with impaired recall. Treat-
ment with ropinirole did not lead to any significant
improvement in symptoms. The disease progressed, they
became bedridden and case F2-III:2 needed a PEG insertion
10 years after the onset of movement problems due to
recurrent aspiration pneumonia, and the proband died in
the late 40s. Case subjects F2-III:4 and F2-III:5 are maternal
first cousins of the index case subject in family 2. They pre-
sented an almost identical phenotype. On a background of
depression, both brothers noted progressive ‘‘slurring’’ of
speech, slowing of all movements, difficulty with walking,
recurrent falls, and poor memory. Examination demon-
strated a similar phenotype with dysarthria, abnormal pur-
suit with frequent saccadic intrusions, pronounced brady-
kinesia, extrapyramidal rigidity, and bilaterally extensor
plantar responses.
The proband in family 3 (F3-II:1) had normal early devel-
opment but later developed mild delay in fine motor and
language milestones that were progressive. He also devel-
oped mild coordination problems and autism spectrum
disorder (ASD) and received special education services at
school age. At age 11 years, repeat neuropsychologicare CT from case subject F3-II:1 demonstrating calcification in the
nd 12 are axial MRI scans from individual F3-II:1 from family 3
T2 MRI, and B12 is Axial Ven Bold reconstruction MRI that is sen-
calcification on MRI.
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Table 1. Clinical Features of Affected Individuals with JAM2 Bi-allelic Variants
Individual
F1-II:2
Individual
F2-III:2
Individual
F2-III:3
Individual
F2-III:4
Individual
F2-III:5
Individual
F3-II:1
Individual
F4-II:3
cDNA sequence c.685C>T c.685C>T c.685C>T c.685C>T c.685C>T c.3951dupG,
c.323G>A
c.177_180delCAGA
Amino acid change p.Arg229Ter p.Arg229Ter p.Arg229Ter p.Arg229Ter p.Arg229Ter IVS4-1dupG,
p.Arg108His
p.Arg60Ter
Zygosity homozygous homozygous homozygous homozygous homozygous compound
heterozygous
homozygous
Gender (male/female) male male female male male male female
Birth and early milestones normal normal normal normal normal normal normal
Onset of symptoms childhood late 20s late 30s teenage teenage childhood early childhood
Symptom at onset cerebellar ataxia and
cognitive decline
cognitive decline,
depression
difficulty walking depression, dysarthria depression, dysarthria autism spectrum
disorder
seizures
Age at examination
(in years)
24 41 39 40 49 15 7
Phenotype at Last Examination
Pyramidal syndrome yes; increased tone,
brisk reflexes,
upgoing plantars
yes; increased tone,
brisk reflexes,
upgoing plantars
yes; increased tone,
brisk reflexes,
upgoing plantars
yes; increased
tone, brisk
reflexes, upgoing
plantars
yes; increased tone,
brisk reflexes,
upgoing plantars
no no
Cerebellar syndrome yes; upper and
lower limb ataxia,
dysarthria, nystagmus
yes; upper and
lower limb ataxia
yes; upper and
lower limb ataxia
yes; upper and
lower limb
ataxia, dysarthria
yes; upper and
lower limb
ataxia, dysarthria
yes; upper and
lower limb mild
ataxia, nystagmus
no
Parkinsonism yes; rigidity,
bradykinesia.
yes; hypophonia,
hypomimia,
bradykinesia
yes; hypophonia,
hypomimia,
bradykinesia
yes; rigidity,
bradykinesia
yes; rigidity,
bradykinesia
no no
Dystonia yes; generalized yes; limb dystonia
and orofacial
dyskinesias
yes; limb dystonia
and orofacial
dyskinesias
no no no no
Other seizures, ophthalmoplegia,
PEG inserted in advance
stage
PEG inserted in
advance stage
became anarthric
in advanced
stage
– – autism spectrum
disorder
–
Cognitive function severe cognitive decline memory decline
with severe
impaired recall
unable to comment
on cognition
due to anarthria.
severe cognitive
decline
severe cognitive
decline
decline in
academic
performance
normal for her age
Brain imaging calcification
pattern
basal ganglia, thalamus,
cerebellum, deep gray
matter
basal ganglia,
thalamus,
cerebellum, deep
gray matter
basal ganglia,
thalamus,
cerebellum,
deep gray matter
basal ganglia,
thalamus,
cerebellum,
deep gray matter
basal ganglia,
thalamus,
cerebellum,
deep gray matter
basal ganglia,
and frontal
cortex
basal ganglia,
dentate nucleus
and cerebellar
hemispheres
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evaluation showed a continuous decline in academic per-
formance. Parents were asymptomatic, an older brother
had some anxiety and hyperactivity, and a younger
brother aged 13 years had mild autistic features. At the
last examination of the proband aged 15 years, he had
autism spectrum features, hyperactivity, developmental
delay, and coordination problems. The coordination diffi-
culties were mild but affected both fine motor skills (but-
tons, zippers, hooks) and complex gross motor tasks. His
learning difficulties were progressive.
The affected member of family 4 (F4-II:3) was born to
Turkish consanguineous parents and presented with sei-
zures when she was 18 months of age; current age is 7.5
years and she has had a total of 3 seizures. Her develop-
ment so far has been in keeping with her peers and her
last examination did not reveal any neurological signs.
Brain calcification was identified on MRI imaging with
bilateral symmetric calcification of the basal ganglia, den-
tate nucleus, and subcortical white matter of cerebellar
hemispheres. Prior to exome sequencing, the known Fahr’s
genes was sequenced and negative.
All seven case subjects reported here had brain calcifica-
tion identified on brain CT and/or MRI imaging. They had
a consistent pattern of bilateral symmetric calcification of
the basal ganglia and deep cortical graymatter. In addition,
the older individuals from families 1 and 2 had severe calci-
fication in the cerebellum folia and the thalamus
(Figure 1B). All families had extensive genetic, metabolic,
and mitochondrial investigations carried out that
excluded acquired and other inherited causes of brain
calcification.
In order to localize the chromosomal location of
the pathogenic variant, we genotyped three affected
and two unaffected individuals from extended family
2 genome-wide by using Illumina HumanCytoSNP-12v2-
1 Beadchip array incorporating 200,000 genetic markers.
Three regions of homozygosity were detected on
chr10:37,414,883–43,132,376, chr13:88,327,643–93,518,
692, and chr21:22,370,881–28,338,710. Next, we per-
formed exome sequencing on probands of families 1 and
2 to identify the causative variant(s). On the assumption
that the disease follows an autosomal-recessive pattern
of inheritance in the families as well as presence of consan-
guinity in two families, we prioritized the bi-allelic
potentially functional variants residing within the runs
of homozygosity. These variants were screened through
all publicly available population databases and our in-
house database. We excluded synonymous variants,
intronic variants (>7 bp from exon boundaries) and com-
mon variants (minor allele frequency > 0.001%). The
selected variants were validated, and segregation analysis
was performed using Sanger sequencing.
In families 1 and 2, filtered exome-sequencing data nar-
rowed down the variants to the same homozygous
nonsense variant (GenBank: NM_021219; c.685C>T
[p.Arg229Ter]) in JAM2 residing within a 5 Mb region of
homozygosity on chr21q21.3 (Figure S1). Sanger416 The American Journal of Human Genetics 106, 412–421, Marchsequencing verified the correct segregation of the variant
on available samples of both families (Figures 1A, 2A,
and 2B). This variant was absent in our in-house exome
database of more than 10,000 exomes, absent in homozy-
gous state in all publicly available databases, and present in
heterozygous state with a minor allele frequency (MAF) of
0.00002 in gnomAD (6/280662). The early stop codon
introduced by c.685C>T is predicted to result in produc-
tion of a truncated protein lacking the transmembrane
and cytoplasmic regions of JAM2 and cause reduction in
total JAM2 as a consequence of nonsense-mediated decay
(NMD) of the mutant transcript. Indeed, RT-PCR analysis
confirmed a reduction of JAM2 mRNA expression levels
in the proband in family 1 compared to the heterozygous
carrier and unrelated control subject (Figure 2C). Further-
more, western blot analysis confirmed the absence of
JAM2 protein in the homozygous proband (Figure 2D).
The reduction of RNA expression and absent JAM2 protein
in the fibroblast cell lines of the proband support the loss-
of-function role of this variant. As JAM2, JAM3, and TJP1
proteins are all junctional components and associated
with brain calcification phenotype, we investigated
whether JAM2 c.685C>T variant affected the localization
of the other two proteins. We show that there was no dif-
ference in the localization of JAM3 and TJP1 in primary
dermal fibroblasts from JAM2 homozygous affected indi-
viduals (Figure S2).
In family 3, Trio-ES revealed compound heterozygous
variants in JAM2 (GenBank: NM_021219; c.3951dupG
[IVS4-1dupG] and c.323G>A [p.Arg108His]). The
c.3951dupG was inherited from the father and
c.323G>A was inherited from the mother. The c.323G>A
was reported once in gnomAD in heterozygous state
(MAF 0.00003, 1/31408), three times in GeneDx in-house
database (MAF 0.00002, 3/167854), and was absent in all
databases as homozygous. It disrupts a highly conserved
residue (CADD:34) and is predicted to be damaging to
the protein function by in silico prediction tools (SIFT,
PROVEAN, Mutation Taster, Mutation Assessor, and Poly-
Phen). The c.3951dupG is predicted to cause the reten-
tion of the canonical splice acceptor site of intron 4 with
insertion of the G nucleotide as the first base of exon 5
causing a frameshift and a truncated protein (p.Val132-
GlyfsX9). This variant was absent from all public databases
and present five times in heterozygous state in GeneDx in-
house database (MAF 0.00003, 5/171284). The variants
segregated fully within the family (Figures 1A, 2A, and 2B).
In family 4, clinical ES uncovered a homozygous 4 bp
deletion in JAM2 (GenBank: NM_021219; c.177_180del-
CAGA [p.Arg60Ter]) (Figures 1A, 2A, and 2B) that causes
a frameshift and an early termination of the protein
affecting the extracellular, transmembrane, and cyto-
plasmic domains of JAM2. The variant was not reported
in any public databases and was predicted pathogenic by
MutationTaster causing loss of function by NMD.
In order to characterize the link between JAM2 variants
and the human neurological phenotype, we developed5, 2020
Figure 2. Validation of JAM2 Variants
Identified in This Study
(A) Validation by Sanger sequencing of the
stop variant c.685C>T (p.Arg229Ter) in
families 1 and 2, the bi-allelic variants in
family 3 (IVS4-1dupG and p.Arg108His),
and the homozygous change in family 4
c.177_180delCAGA (p.Arg60Ter).
(B) Protein structure of JAM2 showing the 2
main domains (Ig-like V-type and Ig-like C2-
type) as well as the variants identified in the
4 families.
(C) Total RNA and protein extracts were pre-
pared from fibroblast cell lines isolated from
the proband of family 1 (HOM), his unaf-
fected mother (HET), and unrelated control
subjects (Con) to assess the c.685C>T
(p.Arg229Ter) JAM2 variant. Agarose gel sep-
aration of RT-PCR products shows a reduc-
tion in JAM2 mRNA expression in the ho-
mozygous proband (HOM) compared to
the proband’s mother (HET) and unrelated
control subject (Con). GAPDH RT-PCR
served as a loading control.
(D) Western blot analysis of total protein ly-
sates using anti-JAM2 and GAPDH (loading
control) antibodies revealed presence of
JAM2 protein in control (Control) and unaf-
fected carrier (HET) cells but complete loss
of JAM2 protein in the homozygous pro-
band of family 1 (HOM). NS, non-specific
band; asterisk, JAM2.jam2 knockout (jam2 KO) mice. Behavioral tests in the
jam2 KO mice showed significant difficulties in beam
walking test and gait abnormalities when compared to
wild-type mice (Figure 3). There was a significant reduction
in stride length (wild-type: 8.145 0.9, jam2 KO: 6.3 5 1;
***p< 0.0001) and increase in sway length (wild-type: 0.13
5 0.14, jam2 KO: 0.95 0.4; **p ¼ 0.002) when comparing
jam2 KO to wild-type littermates’ controls (Figure 3A).
Additionally, the number of missed steps (wild-type: 1.2
5 1.3, jam2 KO: 6.5 5 3.6; *p ¼ 0.017) in the beam-
walking test was higher in jam2 KO compared to controls
(Figure 3B and 3C, Video S2).
Brains of two jam2 KO and two wild-type (C57BL/6)
mice were examined at a young age (6 months old) and
four jam2 KO and four wild-type mice were examined at
an old age (18 months old). In addition, spinal cord sec-
tions from one of the young jam2 KO mice and from all
old jam2 KO and control mice were examined. We
observed prominent widespread vacuolation in the
midbrain and some in the thalamus and cerebral and cere-The American Journal of Humanbellar cortex of young jam2 KO mice.
In the midbrain, the vacuolar change
was accompanied by prominent reac-
tive astrogliosis, mild microglial activa-
tion, and mild reduction in the
neuronal density compared to controls
(Figure 4). Brains of aged jam2 KOmice
showed similar changes, with promi-nent widespread neuropil vacuolation in the midbrain
accompanied by marked astrogliosis, mild microglial acti-
vation, and moderately reduced neuronal density. In
contrast to young jam2 KO mice, there was more promi-
nent vacuolation in the cerebral cortex, thalamus, and
cerebellar cortex and particularly widespread vacuolation
in the cerebellar white matter. To a lesser extent, neuropil
vacuolation in the same regions was also seen in the age-
matched control wild-type mice, suggesting that jam2
KO mice develop age-related changes at a much younger
age, which in some areas, such as cerebellar white matter,
midbrain, thalamus, and cerebellar cortex, increase in
severity with age. In addition, we performed automated
quantification of the neuropil vacuolation on H&E-stained
sections, GFAP immunoreactive gliosis and Iba1-positive
microglial activation in young and aged wild-type and
jam2 KO mice (Figure S3). Automated quantification of
the percentage of vacuolation, gliosis, and microglial acti-
vation in the cortex, midbrain, and cerebellum was per-
formed on digitalized slides, using open source softwareGenetics 106, 412–421, March 5, 2020 417
Figure 3. Behavioral Study on jam2 KO
Mice and Wild-Type (WT)
(A) Representative images of wild-type (left)
and jam2 KO strides (right) in the gait test.
Forepaw (blue) and hindpaw (red). Altered
gait of the jam2 KO mice was analyzed in
stance length, stride, and sway compared
to wild-type (***p < 0.0001, **p ¼ 0.002;
means5 SEM; n ¼ 6 mice per genotype).
(B and C) Walking beam performance on
test day, showing elevated latency to cross
the beam in jam2 KO (*p ¼ 0.017; means
5 SEM; n ¼ 5 wild-type, n ¼ 6 jam2 KO).
See Video S2 for example beam walking
test of a jam2 KO mouse and a control
(wild-type).QuPath. There was a significant increase in the degree of
neuropil vacuolation (p < 0.00007) and astrogliosis (p <
0.0138) in the midbrain of old jam2 KO mice when
compared with age-matched wild-type mice, whereas
Iba1-positive microglial activation in old jam2 KO mice
was less pronounced than in age-matched wild-type mice
(p < 0.035). No mineralization or calcification was
observed in the brains of young or old jam2 KO mice or
controls at the time of examination.
The spinal cord morphology was similar in young and
old jam2 KO-deficient mice but remarkably differed from
that of control mice. The main findings in jam2 KO spinal
cords were widespread neuronal, perivascular, and neuro-
pil mineralization as well as widespread vacuolation in
the gray matter. The mineralized deposits were negative
for PAS and showed weak reactivity for Alcian blue,
excluding calcification, cartilagination, or ossification
stage. The mineralization and vacuolar change were
evident across the gray matter in both anterior and poste-418 The American Journal of Human Genetics 106, 412–421, March 5, 2020rior horns bilaterally and at all levels of
the spinal cord. Although mineraliza-
tion and calcification are known to
occur with age in wild-type mice, in
the four spinal cords from our control
group (age-matched to old jam2 KO
mice), no mineralization or neuropil
vacuolation at any of the spinal cord
levels was observed (Figure S4). JAM3
and TJP1 tight-junction proteins were
investigated in the KO mice, and there
was no difference in localization be-
tween affected and wild-type mice, in
different areas of the brain (Figures S5
and S6).
Mouse models of other brain calcifi-
cation genes have shown brain calcifi-
cation in similar areas to those found
in humans. Such is the case of
Slc20a2-null mice exhibiting progres-
sive calcification of the thalamus, basal
ganglia, and cortex beginning at8 weeks and present in close proximity or within blood ves-
sels and affecting astrocytes and perycites7,9,10 and for my-
org-null mice developing calcifications at 9 months.4 A
study on mice carrying hypomorphic Pdgfb alleles interest-
ingly showed that the calcifications depend on the loss of
endothelial PDGF-B and correlate with the degree of peri-
cyte and BBB deficiency.11 Ocln-null mice present with
similar calcification surrounding blood vessels as seen in
an autopsied case,6 but there were no abnormalities re-
ported in the brain of jam3 KOmice, and there was absence
of Jam3 in the vasculature of the adult mouse brain.5 In our
study, we were not able to detect calcification in the brain of
our jam2 mouse model even though we studied these mice
until the age of 18 months, an age at which other PFBC
models already present calcification and thus it does not
seem to be age related. However, our jam2 KO mice did
show prominent vacuolation, inflammatory response, and
neuronal density reduction in the same areas affected by
calcification in humans. Further studies are needed to
Figure 4. Brain Pathology in Control and jam2 KO Mice of Young (6 Months Old) and Old Age (18 Months Old)
Littermate controls (wild-type) (a, a1–a6) show no significant pathology on (H&E) stained sections (a, cortex; a1, cerebellum; a2,
midbrain) and on immunohistochemistry for astrocytes (GFAP) (a3, midbrain), microglia (Iba1) (a4, midbrain), neuropil (APP) (a5,
midbrain), and neurones (NeuN) (a6, midbrain). In age-matched jam2 KOmice, occasional cortical vacuolation is evident in the cerebral
(b) and cerebellar (b1) cortex and widespread prominent vacuolation is seen in the midbrain (b2). In the midbrain region there is also
marked reactive astrocytosis (b3) and mild microglial activation (b4). APP immunostaining highlights vacuolar change in the neuropil
(b5) and NeuN shows mild reduction in the neuronal density (b6). Aged wild-type mice show occasional vacuolation in the cerebral
(legend continued on next page)
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understand better the disease mechanisms and the differ-
ences between humans and mice for JAM2 and also JAM3.
Together, our results confirm that JAM2 variants underlie
the phenotype in the four families reported here. This im-
plicates JAM2 as a cause of human Mendelian disease.
JAM2 encodes for the junctional-adhesion-molecule-2
(JAM2), member of the junctional adhesion molecules
family, localized in the tight junctions of endothelial cells
and the NVU.12,13 JAM2 is an adhesive ligand interacting
with various immune cell types and regulating vascular
function and was recently identified as an inhibitor of
somatodendritic myelination in spinal cord neurons.14
Junctional adhesion molecules are a family of proteins
that play an important role in the regulation of cell polar-
ity, endothelium permeability, and leukocyte migration
and the blood-brain-barier (BBB) function. In addition to
JAM2, recessive variants in JAM3 and OCLN were linked
to complex neurological disorders presenting with calcifi-
cation in the brain,5,6 suggesting that deregulation of the
central NVU is important in pathogenesis of PFBC. Even
though increased permeability of the BBB hasn’t been
confirmed in jam2 KO mice so far,13 including this study,
mutations have now been identified in three genes encod-
ing tight junction proteins in humans (JAM2, JAM3, and
OCLN), suggesting that loss of cell-to-cell adhesion with
subsequent dysfunction of solute passage is an important
cause of brain calcification. Furthermore, a multicenter
collaboration from China recently described four patients
from three families that presented with PFBC and bi-allelic
mutations in JAM2.15 They interestingly show failure of
JAM2 to translocate to the plasma membrane in JAM2
transfected mutants of hamster ovary cells, and they pro-
pose a cell-to-cell adhesion impairment as the mechanism
causing failure of the NVU and consequent brain calcifica-
tion phenotype. This work further supports our hypothesis
and together with PDGFB, PDGFRB, and MYORG the tight
junction genes solidify dysregulation of BBB integrity as a
key PFBC pathomechanism (Figure S7).
Importantly, we show that the human JAM2-related
neurological phenotype seen is replicated in the jam2 KO
mouse. It is noteworthy that the older human individuals
carrying JAM2 variants, who had longer disease duration,
presented impaired gait of variable severity including
ataxic and/or parkinsonian gait illustrated in the mouse
model. The main walking and behavioral findings in the
affected mice were progressive gait abnormalities, similar
to ataxic mouse, clearly seen on standard mouse pheno-
type assessment. Furthermore, neuropathology of jam2
KO mouse model (prominent vacuolation in the cerebral
cortex, thalamus, and cerebellar cortex and particularlycortex (c), cerebellar cortex (c1), and midbrain (c2) (H&E). There is
activation (c4). No significant disruption of the cytoarchitecture is see
of neuronal loss (c6). In age-matched old jam2 KOmice, there is incre
cerebellar white matter (d1), midbrain (d2), and thalamus (not shown
in the midbrain (d3), but microglial activation remains mildly increa
APP immunostaining (d5). Similar to age-matched littermate controls
KO mouse (d6). Scale bar: 100 mm in a–d, a2–a6, b2–b6, c2–c6, d2–d
420 The American Journal of Human Genetics 106, 412–421, Marchwidespread vacuolation in the midbrain) affected similar
brain areas to those observed on brain imaging of the hu-
man phenotype. The pattern of calcification seen on the
brain scans of our subjects was largely the same as that
seen in PFBC-affected subjects where the brain is structur-
ally normal and the calcification is almost exclusively in
the gray matter affecting basal ganglia, thalamus, deep cor-
tex, dental, and cerebellar folia.16 It was indistinguishable
from SLC20A2, PDGFB, PDGFRB, and XPR1 case subjects
and there was no calcification in the pons as seen in MY-
ORG subjects.1,17 In contrast, the calcification pattern
observed in JAM2 subjects differs to that of other tight
junction genes, as OCLN subjects have band-like calcifica-
tion with simplified gyration6 and JAM3 subjects present
multifocal intraparenchymal hemorrhage, massive cysts,
and subependymal calcification.5
In summary, we show that JAM2 is recurrently mutated
in families with recessive PFBC presenting with a combina-
tion of movement disorder and/or cognitive and psychiat-
ric manifestations. The human phenotype was replicated
in a jam2 KO mouse model. The presence of mutations
in several genes involved in the central NVU presenting
clinically with brain calcification suggests that the NVU
is likely to represent a potential therapeutic target in this
group of disorders.Accession Numbers
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Figure S1: Genome wide illustration of homozygous regions. Three significant regions of 
homozygosity were detected: Chr 10: 37414883-43132376; Chr 13: 88327643-93518692; and 
Chr 21: 22370881-28338710 and they are highlighted in red.  
 
  
  
 Figure S2: Localisation of JAM3 and TJP1 tight junction proteins in primary dermal 
fibroblasts from the proband of Family 1 (Hom) and his unaffected mother (Het). Scale bars =  
50 μm.   
  
  
  
 Figure S3: Quantitative data of neuropil vacuolation, astrogliosis and microglial 
activation in young and old jam2 KO and wild-type (Control) mice. The automated 
quantification of the neuropil vacuolation on H&E stained sections (A, A1, A2, B, B1, B2), 
GFAP immunoreactive gliosis (A3, B3) and Iba1 positive microglial activation (A4, B4) in 
young (A-A4) and aged (B-B4) wild-type (black columns) and jam2 KO (grey columns) mice. 
Automated quantification of the percentage of vacuolation, gliosis and microglial activation in 
selected areas (cortex, midbrain and cerebellum) was performed on digitalised slides, using 
open source software QuPath.  
In young jam2 KO mice (n=2) when compared with age-matched wild-type mice (n=2), there 
was a trend towards greater neuropil vacuolation in the cortex (A), cerebellum (A1) and 
midbrain (A2). Similarly, GFAP positive astrogliosis (A3), but not Iba1 positive microglial 
activation (A4), was more prominent in young jam2 KO mice, than wild-type mice. In the aged 
jam2 KO mice (n=4), there was a trend towards greater neuropil vacuolation in the cortex (B) 
and cerebellum (B1), when compared with age-matched wild-type mice (n=4). There was a 
significant increase in the degree of neuropil vacuolation (*** p<0.00007) and astrogliosis 
(**p<0.0138) in the midbrain (B3) of old jam2 KO mice when compared with age-matched 
wild-type mice, whereas Iba1 positive microglial activation (B4) in old jam2 KO mice was less 
pronounced than in age-matched wild-type mice (*p<0.035). 
  
  
Figure S4: Spinal cord pathology in control mice and jam2 KO mice of young (6 months) 
and old (18 months) age. In the grey matter of young jam2 KO mice (a, a1 and a2) (a1) there 
is frequent mineralisation (yellow arrow) and occasional vacuolation in the neuropil (blue 
arrow). The mineralised deposits show no reactivity with PAS tinctorial stain (a1, yellow 
arrow) and very weak labelling with Alcian blue (a2, yellow arrow). In the spinal cord grey 
matter of old control wild-type mice (b, b1 and b2) there is no mineralisation and no apparent 
neuropil vacuolation. In the spinal cord of an old jam2 KO mouse (c, c1 and c2), however, 
there is frequent mineralisation (c, yellow arrow) and vacuolation in the neuropil (blue arrow) 
involving both anterior and posterior horns. The mineralised deposits also in old jam2 KO mice 
are not positive for PAS (c1) and weakly label for Alcian blue (c2, one yellow arrow 
  
accentuates a mineralised neurone and the other shows perivascular mineralisation).  Scale bar: 
100µm a-c, a1-c1, a2-c2.  
 
 
 
 
  
 Figure S5: Correct localisation of JAM3 and TJP1 tight-junction proteins in the lateral 
ventricle ependyma of jam2 KO and wild-type (WT) mice. Scale bars = 100 μm.  
 
  
 
 Figure S6: Unaltered staining pattern for JAM3 and TJP1 tight-junction proteins in different 
brain regions of jam2 KO and wild-type (WT) mice. Scale bars = 100 μm.  
  
  
 Figure S7: Schematic highlighting the contributions of proteins associated with brain 
calcification disorders in cell types of the central neurovascular unit (NVU). Autosomal 
dominant mutations in genes encoding the inorganic phosphate transporter 2; (PiT2 encoded 
by SLC20A2) and inorganic phosphate exporter; (XPR1 encoded by SLC53A1/XPR1) are 
causative of PFBC, highlighting dysregulation of phosphate homeostasis as an important cause 
of calcium deposition. Platelet-derived growth factor subunit B (PDGF-B encoded by PDGFB) 
signalling through the platelet-derived growth factor receptor-β (PDGFR-β encoded by 
PDGFRB) is important for pericyte survival and blood brain barrier (BBB) maintenance. 
Autosomal dominant mutations in PDGFB and PDGFRB cause PFBC suggesting loss of BBB 
integrity as an additional pathomechanism. In line with this, recessive mutations in JAM3 and 
OCLN encoding tight junction proteins have been associated with complex neurological 
disorders that include brain calcification. The JAM2 mutations identified in this study further 
support dysregulation of BBB integrity as a PFBC pathomechanism. This figure was prepared 
using Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License 
(http://smart.servier.com/). 
  
 Supplemental methods  
This study was approved by UCLH Queen Square ethics committee and local institutional 
review board (UCLH: 04/N034) and informed consent was obtained from all subjects or their 
legal guardians when applicable.   
  
Genome-wide genotyping and homozygosity mapping  
Genomic DNA was extracted from peripheral blood samples. In family 2 genome-wide 
genotyping was performed according to the manufacturers’ instructions on Illumina 
HumanCytoSNP-12v2-1_H array, which contains probes for over 200,000 markers distributed 
across the genome. Default parameters on genome studio software 2010.3 (Illumina) were used 
for clustering and normalization of raw data, and to obtain genotype calls. Regions of 
homozygosity were then analysed with homozygosity mapper software1.  
  
Exome sequencing (ES)  
ES was performed in all families. In familied 1 and 2 exome sequencing was done with 
Illumina® Nextera focused exome capture on a HiSeq 2000. Paired-end sequence reads were 
aligned with Novoalign against the reference human genome (UCSC hg19). Duplicate read 
removal, format conversion, and indexing were performed with Picard. The Genome Analysis 
Toolkit (GATK) was used to recalibrate base quality scores, perform local realignments around 
possible indels, and to call and filter the variants. Annotated variant files were generated using 
ANNOVAR2. ES in family 3 was carried by GeneDx. Using genomic DNA from the proband 
and parents, the exonic regions and flanking splice junctions of the genome were captured using 
the Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA). Massively parallel 
(NextGen) sequencing was done on an Illumina system with 100bp or greater paired-end reads. 
Reads were aligned to human genome build GRCh37/UCSC hg19, and analyzed for sequence 
variants using a custom-developed analysis tool. Additional sequencing technology and variant 
interpretation protocol has been previously described3. The general assertion criteria for variant 
classification are publicly available on the GeneDx ClinVar submission page 
(http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/). ES in the proband of family 4 was 
performed using the capture system from Twist Human Core Exome Plus kit (Twist 
Bioscience®) and sequenced on a Illumina HiSeqX that produced 150-bp paired-end reads. 
Sequencing data were aligned using BWA software and alignments were converted to binary 
bam file format with GATK. For variant calling we utilized the GATK HaplotypeCaller. 
Additional sequencing and bioinformatics information on this case was previously described4.  
  
Cell culture  
Fibroblasts from one proband and his mother from Family 1 and unrelated controls were 
cultured from a skin biopsy in Dulbecco's modified Eagle medium containing 4.5 g/L glucose 
and supplemented with 10 % heat-inactivated fetal calf serum and maintained in a humidified 
chamber at 37 °C with 5 % CO2.   
  
RT-PCR  
RNA was extracted from human fibroblasts and purified using the Quick-RNA Miniprep Kit 
(Zymo Research). A complementary DNA (cDNA) library was immediately created from 500 
ng of the RNA obtained, by reverse transcription reaction with Superscript II reverse 
transcriptase (Thermofisher). Reverse transcription PCR (RT-PCR) was then performed using 
equal volumes of cDNA using FastStart Taq DNA polymerase master mix and primer pairs 
specific for GAPDH (loading control) and JAM2 (Supplementary Table 1). Equal volumes of 
the PCR mixes were then separated by DNA gel electrophoresis through 1.2% w/v agarose 
TAE. Dye-terminator sequencing reactions were performed using the BigDye® Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems) and analysed on a 3730xl DNA Analyser 
(Applied Biosystems).  
 The primers used for RT-PCR were:  
Target  Forward Primer (5’-3’)  Reverse Primer (5’-3’)  Product  
(bp)  
GAPDH  TGGTGCTGAGTATGTCGTGGAGT  AGTCTTCTGAGTGGCAGTGATGG  292  
JAM2  GTGACAAGAAGTGATGCGGG  GCATAGCATACACCAAGGCC  488  
 
SDS-PAGE and Western blotting  
Cell lysates were prepared by washing cells with cold PBS, followed by lysis buffer addition 
(50 mM Tris, 0.1 mM EGTA, 1 mM EDTA, 0.27 M sucrose, 1 % Triton X-100, Protease 
Inhibitor Cocktail (Roche) Phosphatase Inhibitor Cocktail (Sigma). Cell lysates were then 
collected and clarified by centrifugation at 12,500 rpm for 10 minutes at 4°C. Proteins were 
separated on Novex precasted SDS-PAGE Bis-Tris 4-12% gels (Invitrogen), using MES 
running buffer (Invitrogen). Proteins were then transferred to PVDF membranes (Millipore), 
blocked with 5 % milk and blotted with JAM2 (ThermoFisher PA5-21576) and GAPDH as 
loading control.  
Animal studies  
The mouse strain used in this study is Jam2tm1.2Rha for both jam2 (encoding for Jam-B) knockout 
(KO) and wild-type (WT) mice. Mice were housed in the animal facility and were maintained 
on a 12-hour light dark cycle at a constant temperature and humidity. All animal experiments 
were carried out according to the UK Animal Act 1986 and approved by the UCL Animal Care 
Committee.   
  
Generation of jam-2 deficient mice  
The generation of this colony was previously described in the literature5. Briefly, a jam2 
(ortholog of human JAM2) gene fragment containing exon 5 was flanked by loxP recognition 
sites for Cre recombinase. Within the loxP-flanked region, a murine jam2 cDNA fragment  
(codons 165-298, PEY…SFII*) followed by the bovine growth hormone polyadenylation 
signal (pA) was fused to a BspE1 site in exon 5. The construct also contained a neomycin 
resistance cassette surrounded by frt sites enabling Flp recombinase-mediated removal, as well 
as long (9 kb, 5′) and short (1.65 kb, 3′) arms for homologous recombination. Electroporated 
and G418-selected embryonic stem cell clones were analysed by Southern blot hybridization 
and polymerase chain reaction (PCR). For PCR screening, a primer pair, derived from exon 4 
and the intronic jam-2 sequence flanking the 5’ loxP site, amplified a 345 bp band from WT  
chromosomes and a 450bp band from transgenic chromosomes (primers were 5′- 
AGACCGTGCTGAGATGATAGA-3′ and 5′-CCGAAGGAAGTGTCTAGTAAT-3′). Three  
independent lines were generated and maintained in a mixed 129Sv × C57BL/6 background. 
jam-2 deficient mutants were generated by crossbreeding with the PGK-Cre line followed by 
interbreeding jam2 KO/+ heterozygotes. Mice used in the present study were backcrossed for 
more than 12 generations on C57Bl/6 background.  
  
Behavioural studies  
Behavioural studies were performed in the jam2 KO mice and compared to controls as 
described6. All mice were trained before the relevant tests. The balance beam walking test 
assesses mouse's ability to maintain balance while traversing a narrow beam to reach a safe 
platform by counting and comparing the number of missed steps between jam2 KO and control 
mice. The footprint analysis assesses motor coordination and synchrony by examining gait 
during normal walking. The fore and hind paws were painted with dyes of different colours 
and the mice were encouraged to walk in a straight line over absorbent paper. Stance, stride 
and sway measurements were compared among groups. A Mann-Whitney test (means ± SEM) 
was used to analyse the results of the behavioural tests.    
  
Histological analysis   
Mice were culled by injection of a pentobarbital overdose. The brains and the spinal cords were 
harvested and fixed in formalin. After formalin fixation the brains were cut sagittaly and the 
cervical, thoracic and lumbar spinal cord segments were cut transversely and processed for 
paraffin histology. The 5µm thin sections of the tissue were stained with haematoxylin and 
eosin (H&E) for routine examination. Representative sections from each brain and spinal cord 
were further assessed with Alcian Blue (Alcian Blue: Sigma, C174240; Gill III Haematoxylin: 
Thermo Shandon, 6765009, Schiffs: VWR, 351204L) and PAS (Ventana PAS Kit, Ventana  
860-014) tinctorial stains and with immunohistochemical stains for Iba1 (Wako, 019-19741,  
1:250), GFAP (Agilent, Z0334, 1:1000 ), NeuN (Chemicon, MAB377, 1:2000) and APP  
(Millipore, MAB348, 1:800). The Alcian Blue was hand-stained. The PAS tinctorial stain and 
immunostainings were performed on a ROCHE Ventana Discovery automated staining 
platform following the manufacturer’s guidelines. Biotinylated secondary antibodies and a 
horseradish peroxidase-conjugated streptavidin complex and diaminobenzidine as a 
chromogen were used for the immunostainings.  All staining was carried out with appropriate 
controls.   
 
Automated quantification of histological results 
For image analysis and automated pathology quantification, histological slides were first 
digitised on a LEICA SCN400F scanner (LEICA Milton Keynes, UK) at x40 magnification 
and 65% image compression setting during export. Then, from whole digitalised slides, the full 
thickness of cortex, entire midbrain and entire cerebellar white matter with cortical granule cell 
layer was manually selected for quantification studies. The percentage of neuropil vacuolation 
on H&E stained sections, astrogliosis on GFAP immunostained sections and microglial 
activation on Iba1 immunostained slides in the manually selected cortical, midbrain and 
cerebellar regions was quantified, using an algorithm developed on open source digitalised 
image analysis software QuPath (v.0.2.0-m8)7.  The difference of analysed parameters between 
wild-type and jam2 KO mice in both young and old cohorts was analysed in Excel using paired 
t-test (with unequal variances), with p < 0.05 considered statistically significant. 
Immunofluorescence analysis  
Fibroblasts were fixed with 4% v/v formaldehyde in Dulbecco's Phosphate-Buffered Saline 
(DPBS) for 15 min at room temperature (RT). Slices of mouse brain were prepared as descried 
above for histological analysis. Cells/brain slices were incubated in blocking and 
permeabilisation solution (BPS) consisting of: 10% v/v donkey serum, 0.1% w/v triton-x100 
in DPBS for 1 hr. Cells/slices were then incubated with primary antibodies diluted in BPS 
targeting JAM3/JAM-C (goat anti-JAM-C, RnD Systems AF1213, 10μg/ml), and TJP1 (Mouse 
anti-ZO-1, Thermofisher Scientific 339100, 5μg/ml) for 2 hrs. This was followed by incubation 
with donkey anti-goat Alex Fluor-488 (Thermofisher A11055, 1:1000) and donkey anti-mouse 
Alex Fluor-568 (Thermofisher a10037, 1:1000) fluorescently conjugated antibodies, and 
phalloidin-647 for 1 hr. Nuclei were counterstained with 0.1 μg/ml 4′,6-diamidino-
2phenylindole (DAPI) and mounted with mounting medium (Dako) for confocal microscopy. 
Images were acquired with a Zeiss 710 VIS CLSM equipped with a META detection system 
using 20x and 63x (oil immersion) objectives, and max intensity projections prepared using 
ImageJ FIJI software.   
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